Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 5/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | CPA1 | P15085 | 3/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259900 | 1.00 | L3MBTL1 (0.49) | L3MBTL1PTPN1CA1CA12CA9 | |
| SCHEMBL4261543 | 0.92 | L3MBTL1 (0.47) | L3MBTL1CTSBCTSSCTSKMEN1 | |
| SCHEMBL4261539 | 0.92 | L3MBTL1 (0.47) | L3MBTL1CTSBCTSSCTSKMEN1 | |
| SCHEMBL4267590 | 0.84 | MMP2 (0.58) | ALDH1A1 | |
| SCHEMBL4267594 | 0.84 | MMP2 (0.58) | ALDH1A1 | |
| SCHEMBL6510445 | 0.80 | KDM4E (0.50) | L3MBTL1MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL4275272 | 0.80 | PPARA (0.59) | PTPN1 | |
| SCHEMBL28965836 | 0.77 | PTPN1 (0.66) | L3MBTL1PTPN1CA1CA12CA9 | |
| SCHEMBL28965835 | 0.77 | PTPN1 (0.66) | L3MBTL1PTPN1CA1CA12CA9 | |
| SCHEMBL2632872 | 0.75 | PTPN1 (0.74) | L3MBTL1PTPN1CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082392-A1 | Substituted Carboxylic Acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC | 2009-03-26 | — | — | US | claimed |
| US-20040266788-A1 | Substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2004-12-30 | — | — | US | claimed |
| US-20090082392-A1 | Substituted Carboxylic Acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC | 2009-03-26 | — | — | US | disclosed |
| US-7358364-B2 | treatment of diabetes and/or cancer; useful in the treatment of syndrome X; capable of inhibiting Protein tyrosine phosphatase | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20040266788-A1 | Substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266788-A1 | Substituted carboxylic acids | PTP4A1, PTPRS, G6PC1 | L3MBTL1 4045/4885PTPN1 11/4885CA1 1086/4885 |
| US-20090082392-A1 | Substituted Carboxylic Acids | PTPRJ, PTPRS, PTPRG | L3MBTL1 4466/4885PTPN1 16/4885CA1 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.